ViiV’s Vocabria (cabotegravir, tablet formulation) Receives the US FDA’s Approval for the Treatment of HIV-1 infection

 ViiV’s Vocabria (cabotegravir, tablet formulation) Receives the US FDA’s Approval for the Treatment of HIV-1 infection

Shots:

  • The US FDA approved Vocabria (30mg, tablet formulation) in combination with oral rilpivirine (Edurant) for one month prior to starting treatment with Cabenuva to ensure the medications are well-tolerated before switching to the extended-release injectable formulation
  • Additionally, changes to the Edurant (rilpivirine) tablet label were revised to reflect the oral lead-in recommendations for use with Vocabria
  • The oral therapy is for the patients who will miss planned injection dosing with Cebenuva

Click here ­to­ read full press release/ article | Ref: FDA | Image: StraitTimes

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post